JP5834004B2 - ループス治療のための方法および組成物 - Google Patents

ループス治療のための方法および組成物 Download PDF

Info

Publication number
JP5834004B2
JP5834004B2 JP2012511015A JP2012511015A JP5834004B2 JP 5834004 B2 JP5834004 B2 JP 5834004B2 JP 2012511015 A JP2012511015 A JP 2012511015A JP 2012511015 A JP2012511015 A JP 2012511015A JP 5834004 B2 JP5834004 B2 JP 5834004B2
Authority
JP
Japan
Prior art keywords
antibody
cells
mouse
mice
lupus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012511015A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012526846A5 (OSRAM
JP2012526846A (ja
Inventor
ジョアン エム． カプラン，
ジョアン エム． カプラン，
ブルース エル． ロバーツ，
ブルース エル． ロバーツ，
ウィリアム エム． サイダーズ，
ウィリアム エム． サイダーズ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of JP2012526846A publication Critical patent/JP2012526846A/ja
Publication of JP2012526846A5 publication Critical patent/JP2012526846A5/ja
Application granted granted Critical
Publication of JP5834004B2 publication Critical patent/JP5834004B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
JP2012511015A 2009-05-13 2010-05-13 ループス治療のための方法および組成物 Active JP5834004B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17792409P 2009-05-13 2009-05-13
US61/177,924 2009-05-13
PCT/US2010/034741 WO2010132683A1 (en) 2009-05-13 2010-05-13 Methods and compositions for treating lupus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014250861A Division JP2015052021A (ja) 2009-05-13 2014-12-11 ループス治療のための方法および組成物

Publications (3)

Publication Number Publication Date
JP2012526846A JP2012526846A (ja) 2012-11-01
JP2012526846A5 JP2012526846A5 (OSRAM) 2013-06-27
JP5834004B2 true JP5834004B2 (ja) 2015-12-16

Family

ID=43085330

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012511015A Active JP5834004B2 (ja) 2009-05-13 2010-05-13 ループス治療のための方法および組成物
JP2014250861A Withdrawn JP2015052021A (ja) 2009-05-13 2014-12-11 ループス治療のための方法および組成物
JP2016197833A Pending JP2017008106A (ja) 2009-05-13 2016-10-06 ループス治療のための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014250861A Withdrawn JP2015052021A (ja) 2009-05-13 2014-12-11 ループス治療のための方法および組成物
JP2016197833A Pending JP2017008106A (ja) 2009-05-13 2016-10-06 ループス治療のための方法および組成物

Country Status (12)

Country Link
US (2) US9617343B2 (OSRAM)
EP (2) EP2429583A4 (OSRAM)
JP (3) JP5834004B2 (OSRAM)
KR (1) KR101800467B1 (OSRAM)
CN (2) CN110179989B (OSRAM)
AU (2) AU2010248935B2 (OSRAM)
BR (1) BRPI1013927A2 (OSRAM)
CA (1) CA2761885A1 (OSRAM)
IL (1) IL216146A0 (OSRAM)
MX (1) MX342907B (OSRAM)
RU (1) RU2607022C2 (OSRAM)
WO (1) WO2010132683A1 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY160126A (en) 2009-05-13 2017-02-28 Genzyme Corp Anti-human cd52 immunoglobulins
US20150073043A1 (en) * 2012-01-19 2015-03-12 Institut Pasteur Of Shanghai, Chinese Academy Of Sciences Use of phosphorylation pathway-related factor in regulating function of regulatory t cell
JP6400604B2 (ja) * 2013-02-08 2018-10-03 アレゲーニー・シンガー リサーチ インスティチュート プレループス診断用バイオマーカーとしての細胞結合性補体活性産物
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
CN105051544B (zh) 2013-03-20 2018-11-23 豪夫迈·罗氏有限公司 小鼠血清中大鼠抗体的特异性检测
PT3105317T (pt) * 2014-02-14 2019-02-27 Cellectis Células para imunoterapia manipuladas para atuar sobre antigénios presentes tanto em células imunitárias como em células patológicas
KR102632082B1 (ko) * 2015-02-27 2024-02-02 아이셀 진 테라퓨틱스 엘엘씨 혈액 악성종양을 표적으로 하는 키메라 항원 수용체(car), 조성물 및 이의 용도
CN115058395B (zh) 2015-06-25 2025-07-18 美商生物细胞基因治疗有限公司 嵌合抗原受体(car)、组合物及其使用方法
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
WO2017222593A1 (en) 2016-06-24 2017-12-28 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars), compositions and methods thereof
CN118853581A (zh) 2017-06-21 2024-10-29 美商生物细胞基因治疗有限公司 嵌合抗原受体(CARs)、组合物及其使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
US7060802B1 (en) * 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
WO2004042032A2 (en) * 2002-11-01 2004-05-21 The Ohio State University Research Foundation Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
US20060228351A1 (en) 2003-03-31 2006-10-12 Junichi Masuyama Method of inducing differentiation and proliferating regulatory t cell by anti-cd52 antibody and medicinal composition therefor
CN1898267B (zh) 2003-11-01 2012-05-23 默克专利股份有限公司 修饰的抗cd52抗体
CA2562771C (en) 2004-04-12 2013-04-09 Medimmune, Inc. Anti-il-9 antibody formulations and uses thereof
CN101443040A (zh) * 2006-03-16 2009-05-27 基因技术股份有限公司 用cd4抗体治疗狼疮的方法
JP2009533350A (ja) 2006-04-07 2009-09-17 キメロス， インコーポレイテッド Ｂ細胞悪性疾患を処置するための組成物および方法
JP5541915B2 (ja) * 2006-04-12 2014-07-09 ジェンザイム・コーポレーション 自己免疫疾患を治療する方法
GB0608054D0 (en) 2006-04-24 2006-05-31 Isis Innovation Production and use of regulatory t cells
CA2653848A1 (en) * 2006-05-31 2007-12-06 Genzyme Corporation Methods of using anti-thymocyte globulin and related agents
AU2007275654A1 (en) 2006-07-19 2008-01-24 The Trustees Of The University Of Pennsylvania WSX-1/p28 as a target for anti-inflammatory responses
US8148067B2 (en) 2006-11-09 2012-04-03 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
MY160126A (en) 2009-05-13 2017-02-28 Genzyme Corp Anti-human cd52 immunoglobulins
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52

Also Published As

Publication number Publication date
KR101800467B1 (ko) 2017-11-22
AU2010248935B2 (en) 2016-12-15
CN102438654A (zh) 2012-05-02
BRPI1013927A2 (pt) 2016-04-05
JP2015052021A (ja) 2015-03-19
RU2607022C2 (ru) 2017-01-10
US20120070408A1 (en) 2012-03-22
EP3345620B1 (en) 2024-08-28
JP2017008106A (ja) 2017-01-12
MX342907B (es) 2016-10-17
WO2010132683A1 (en) 2010-11-18
US20170369583A1 (en) 2017-12-28
AU2017201771A1 (en) 2017-04-06
KR20140014392A (ko) 2014-02-06
RU2011150495A (ru) 2013-06-20
CN110179989B (zh) 2022-06-24
IL216146A0 (en) 2012-01-31
CA2761885A1 (en) 2010-11-18
EP2429583A1 (en) 2012-03-21
US9617343B2 (en) 2017-04-11
MX2011012048A (es) 2011-12-12
EP3345620A1 (en) 2018-07-11
AU2010248935A1 (en) 2011-11-17
JP2012526846A (ja) 2012-11-01
CN110179989A (zh) 2019-08-30
EP2429583A4 (en) 2013-10-16

Similar Documents

Publication Publication Date Title
JP5834004B2 (ja) ループス治療のための方法および組成物
CN105392497B (zh) 以il-4r抑制剂治疗嗜酸性食管炎的方法
US20120058082A1 (en) Methods and compositions for treatment
TW202332696A (zh) 治療發炎症狀的方法
JP2005536511A (ja) ４−１ｂｂ結合物質を用いる治療及び予防
TW202302143A (zh) 重症肌無力症之治療或預防用之醫藥組合物
CN102548573A (zh) Nkg2d抑制剂在治疗心血管和代谢疾病如2型糖尿病中的用途
US12144859B2 (en) B cell depleting agent for the treatment of atherosclerosis
KR20250067121A (ko) Cnx 항원-결합 분자
US20250074981A1 (en) Combination therapy with dexamethasone and tumor-specific t cell engaging multi-specific antibodies for treating cancer
JP2022116272A (ja) Ｔ１ｄｍ及び膵島炎の治療に使用するための抗ｃｄ４０抗体
JP7475011B2 (ja) Ｈｔｌｖ－１関連脊髄症（ｈａｍ）治療又は予防剤、及びｈａｍの治療方法
HK1255653A1 (en) Methods and compositions for treating lupus
HK1255653B (en) Methods and compositions for treating lupus
JP2022546686A (ja) 形質細胞に対する抑制剤または細胞傷害剤を使用する慢性疲労症候群の処置のための方法
US20060165689A1 (en) Compositions and methods for modulation of effects on phagocyte and lymphoid cell populations employing tirc7
JP2001527410A (ja) 好酸球の枯渇のための方法およびそのための組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140611

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140909

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140917

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141010

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141110

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20141211

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150709

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150826

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151005

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151030

R150 Certificate of patent or registration of utility model

Ref document number: 5834004

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250